“…The FDA (Food and Drug Administration) has approved olaparib and talazoparib for the treatment of TNBC patients with BRCA1/2 mutations ( Table 1 , Table 2 and Table 3 ) [ 16 , 35 , 36 , 37 , 38 , 39 ]. Researchers from the field have reported that HR mechanisms also repair genetic mutations other than those in BRCA genes, such as CDK12 , RAD51B , RAD51C , RAD51D , CHEK1 , CHEK2 , FANCA , FANCC , FANCD2 , FRANCE , FANCF , ATM , PALB2 , NBS1 , ATR , BAP1 , WRN , MRE11A , and BLM [ 3 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ]. Similar treatment responses in cancers with BRCA ness and BRCA1/2 -mutated tumors have been observed [ 3 , 16 ].…”